替吉奥联合洛铂同步放化疗治疗中晚期食管癌疗效观察

Efficacy observation of S-1 plus lobaplatin in the treatment of advanced esophageal cancer by concurrent chemoradiotherapy

目的:观察替吉奥联合洛铂同期放化疗治疗中晚期食管癌的疗效。方法:将75例中晚期食管癌患者随机分为观察组(n=37例)和对照组(n=38例)。观察组采用放疗联合替吉奥胶囊60 mg/m2口服化疗+洛铂25 mg/m2静脉化疗,对照组采用放疗联合5FU 750 mg/m2+顺铂40 mg/m2静脉化疗。放化疗结束后4周评价近期疗效和毒性反应,并随访患者1年,2年生存率。结果:所有患者均可评价疗效。观察组和对照组近期有效率分别为89.2%和48.4%,差异有统计学意义(P<0.05)。1年生存率分别为86.4%和63.1%,差异有统计学意义(P<0.05),2年生存率分别为64.8%和31.9%,差异有统计学意义(P<0.05)。观察组血小板下降率高于对照组,但恶心呕吐及白细胞下降率明显低于对照组,放射性食管炎发生率两组差异无统计学意义(P>0.05)。结论:替吉奥联合洛铂同步放化疗治疗中晚期食管癌疗效切确,不良反应更低。

Objective To observe efficacy of（Tegafur,Gimeracil and Oteracil Potassium Capsules） S-1 plus lobaplatin in the treatment of advanced esophageal cancer by concurrent chemoradiotherapy. Method 75 patients with advanced esophageal cancer were randomly divided into treatment group（ n = 37） and control group（ n = 38）,Treatment group was given S-1 60 mg /m2,po,plus lobaplatin 25 mg/m2 Intravenous chemotherapy,Control group were given 5FU 750 mg / m2＋ DDP 40 mg / m2 Intravenous chemotherapy,Each group were received three dimensional conformal radiation therapy. Efficacy and toxicity were evaluated after the end of chemotherapy about 4 weeks. Results The overall response in Treatment group and Control were 89. 2% and48. 4% respectively（ P〈0. 05）,1-year survival rates were 86. 4% and 63. 1%（ P〈0. 05）,2-year survival rates were64. 8% and 31. 9%（ P〈0. 05）. Treatment group had higher platelet decline rate got a lower nausea and vomiting and leukopenia rate,there was no difference in the incidence of radiation esophagitis（（ P〉0. 05））. Conclusion S1 plus lobaplatin concurrent chemoradiotherapy in the treat of advanced esophageal cancer are high efficacy and low side effects.